$AIMイムノテック(AIM.US)$AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
$AIMイムノテック(AIM.US)$ NEWS AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
$AIMイムノテック(AIM.US)$AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
$AIMイムノテック(AIM.US)$AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions 2 MINUTES AGO, 8:50 AM EST VIA GLOBENEWSWIRE
$AIMイムノテック(AIM.US)$AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer 3 MINUTES AGO, 9:10 AM EST VIA GLOBENEWSWIRE
$AIMイムノテック(AIM.US)$AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
$AIMイムノテック(AIM.US)$AIM ImmunoTech Issued Two US Patents Titled 'Compositions for Cancer Therapy and Methods' And 'Methods for Improving Exercise Tolerance in Myalgic Encephalomyelitis Patients'
$AIMイムノテック(AIM.US)$AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions 12 MINUTES AGO, 12:00 PM EST VIA GLOBENEWSWIRE AIM SHARE No severe adverse events reported to date Topline data expected as early as Q1 2024
CEO of AIM, Thomas K. Equels, highlights their robust cash position enabling strong clinical and operational performance. He also brings attention to the company's ovarian and pancreatic cancer programs, forecasting value-boosting milestones ahead from them.
AIMイムノテックに関するコメント
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
まだコメントはありません